Novel Ultrasound and DCE-MRI Analyses After Antiangiogenic Treatment With a Selective VEGF Receptor Inhibitor

Ultrasound in Medicine and Biology

Volumn 37, Issue 6, 2011, Pages 909-921

  Watson, Katherine D ^a,b   Hu, Xiaowen ^a   Lai, Chun Yen ^a   Lindfors, Heather A ^a   Hu Lowe, Dana D ^c   Tuthill, Theresa A ^c   Shalinsky, David R ^c   Ferrara, Katherine W ^a  

^a University of California Davis   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c PFIZER INC   (United States)

Author keywords

AG 028262; CPS; Destruction replenishment ultrasound; Dynamic contrast enhanced MRI; Perfusion; Tumor blood flow; VEGF R

Indexed keywords

AG-028262; CPS; DESTRUCTION-REPLENISHMENT ULTRASOUND; DYNAMIC CONTRAST-ENHANCED MRI; PERFUSION; VEGF-R;

AMINO ACIDS; FLOW RATE; MAGNETIC RESONANCE; MAGNETIC RESONANCE IMAGING; TUMORS;

ULTRASONICS;

AG 028262; ECHO CONTRAST MEDIUM; GADOLINIUM PENTETATE; UNCLASSIFIED DRUG; VASCULOTROPIN INHIBITOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ARTICLE; BREAST ADENOCARCINOMA; CONTRAST ENHANCEMENT; CONTROLLED STUDY; DRUG EFFICACY; ECHOGRAPHY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; RAT; REPRODUCIBILITY; TUMOR BLOOD FLOW; TUMOR REGRESSION;

ADENOCARCINOMA; ANGIOGENESIS INHIBITORS; ANIMALS; CELL LINE, TUMOR; DIFFUSION MAGNETIC RESONANCE IMAGING; FEMALE; MALE; MAMMARY NEOPLASMS, EXPERIMENTAL; NEOVASCULARIZATION, PATHOLOGIC; RATS; RATS, INBRED F344; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; TREATMENT OUTCOME; ULTRASONOGRAPHY;

EID: 79956071970     PISSN: 03015629     EISSN: 1879291X     Source Type: Journal    
DOI: 10.1016/j.ultrasmedbio.2011.03.001     Document Type: Article

References (70)

1. Averkiou M., Lampaskis M., Kyriakopoulou K., Skarlos D., Klouvas G., Strouthos C., Leen E. Quantification of tumor microvascularity with respiratory gated contrast enhanced ultrasound for monitoring therapy. Ultrasound Med Biol 2010, 36:68-77.
2. Bartels E., Henning S., Wellmer A., Giraldo-Velasquez M., Kermer P. Evaluation of cerebral perfusion deficit in stroke patients using new transcranial contrast imaging CPS technology-Preliminary results. Ultraschall Med 2005, 26:478-486.
3. Bauditz J., Schade T., Wermke W. [Sonographic diagnosis of hilar cholangiocarcinomas by the use of contrast agents]. Ultraschall Med 2007, 28:161-167.
4. Bohs L.N., Trahey G.E. A novel method for angle independent ultrasonic imaging of blood flow and tissue motion. IEEE Trans Biomed Eng 1991, 38:280-286.
5. Brasch R., Turetschek K. MRI characterization of tumors and grading angiogenesis using macromolecular contrast media: Status report. Eur J Radiol 2000, 34:148-155.
6. Broumas A.R., Pollard R.E., Bloch S.H., Wisner E.R., Griffey S., Ferrara K.W. Contrast-enhanced computed tomography and ultrasound for the evaluation of tumor blood flow. Invest Radiol 2005, 40:134-147.
7. Calamante F., Vonken E.J., van Osch M.J. Contrast agent concentration measurements affecting quantification of bolus-tracking perfusion MRI. Magn Reson Med 2007, 58:544-553.
8. Chomas J.E., Dayton P., Allen J., Morgan K., Ferrara K.W. Mechanisms of contrast agent destruction. IEEE Trans Ultrason Ferroelectr Freq Control 2001, 48:232-248.
9. Chomas J.E., Pollard R.E., Sadlowski A.R., Griffey S.M., Wisner E.R., Ferrara K.W. Contrast-enhanced US of microcirculation of superficially implanted tumors in rats. Radiology 2003, 229:439-446.
10. Chou C.-P., Wu M.-T., Chang H.-T., Lo Y.-S., Pan H.-B., Degani H., Furman-Haran E. Monitoring breast cancer response to neoadjuvant systemic chemotherapy using parametric contrast-enhanced MRI: A pilot study. Academic Radiol 2007, 14:561-573.
11. Dayton P.A., Ferrara K.W. Targeted imaging using ultrasound. J Magn Reson Imaging 2002, 16:362-377.
12. Diggle P. Analysis of longitudinal data 2002, Oxford University Press, Oxford, New York.
13. Dijkmans P.A., Knaalpen P., Aiazian E., Visser C.A., Lammertsma A.A., Visser F.C., Kamp O. Myocardial perfusion as measured with real-time myocardial contrast echocardiography in healthy volunteers correlates with positron emission tomography. Circulation 2004, 110. 718-718.
14. Du R., Lu K.V., Petritsch C., Liu P., Ganss R., Passegue E., Song H., Vandenberg S., Johnson R.S., Werb Z., Bergers G. HIF1α induces the recruitment of bone marrow-derived vascular modulatory cells to regulate tumor angiogenesis and invasion. Cancer Cell 2008, 13:206-220.
15. Ebos J.M., Lee C.R., Cruz-Munoz W., Bjarnason G.A., Christensen J.G., Kerbel R.S. Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell 2009, 15:232-239.
16. El Khouli R.H., Macura K.J., Barker P.B., Habba M.R., Jacobs M.A., Bluemke D.A. Relationship of temporal resolution to diagnostic performance for dynamic contrast enhanced MRI of the breast. J Magn Reson Imaging 2009, 30:999-1004.
17. Elkington A.G., He T., Gatehouse P.D., Prasad S.K., Firmin D.N., Pennell D.J. Optimization of the arterial input function for myocardial perfusion cardiovascular magnetic resonance. J Magn Reson Imaging 2005, 21:354-359.
18. Ellis L.M., Reardon D.A. Cancer: The nuances of therapy. Nature 2009, 458:290-292.
19. Feinstein S.B. The powerful microbubble: From bench to bedside, from intravascular indicator to therapeutic delivery system, and beyond. Am J Physiol Heart Circ Physiol 2004, 287:H450-H457.
20. Foster F.S., Burns P.N., Simpson D.H., Wilson S.R., Christopher D.A., Goertz D.E. Ultrasound for the visualization and quantification of tumor microcirculation. Cancer Metastasis Rev 2000, 19:131-138.
21. Gore J.C., Yankeelov T.E., Peterson T.E., Avison M.J. Molecular imaging without radiopharmaceuticals?. J Nucl Med 2009, 50:999-1007.
22. Harrer J.U., Hornen S., Oertel M.F., Stracke C.P., Klotzsch C. Comparison of perfusion harmonic imaging and perfusion MR imaging for the assessment of microvascular characteristics in brain tumors. Ultraschall Med 2008, 29:45-52.
23. Hilf R., Michel I., Bell C., Freeman J.J., Borman A. Biochemical and morphologic properties of a new lactating mammary tumor line in the rat. Cancer Res 1965, 25:286-299.
24. Horsfield M.A., Thornton J.S., Gill A., Jager H.R., Priest A.N., Morgan B. A functional form for injected MRI Gd-chelate contrast agent concentration incorporating recirculation, extravasation and excretion. Phys Med Biol 2009, 54:2933-2949.
25. Hoyt K., Warram J.M., Umphrey H., Belt L., Lockhart M.E., Robbin M.L., Zinn K.R. Determination of breast cancer response to bevacizumab therapy using contrast-enhanced ultrasound and artificial neural networks. J Ultrasound Med 2010, 29:577-585.
26. Jiang J., Hall T.J. A parallelizable real-time motion tracking algorithm with applications to ultrasonic strain imaging. Phys Med Biol 2007, 52:3773-3790.
27. Kholmovski E.G., DiBella E.V. Perfusion MRI with radial acquisition for arterial input function assessment. Magn Reson Med 2007, 57:821-827.
28. Krix M., Plathow C., Kiessling F., Herth F., Karcher A., Essig M., Schmitteckert H., Kauczor H.U., Delorme S. Quantification of perfusion of liver tissue and metastases using a multivessel model for replenishment kinetics of ultrasound contrast agents. Ultrasound Med Biol 2004, 30:1355-1363.
29. Laird N.M., Ware J.H. Random-effects models for longitudinal data. Biometrics 1982, 38:963-974.
30. Lamuraglia M., Escudier B., Chami L., Schwartz B., Leclere J., Roche A., Lassau N. To predict progression-free survival and overall survival in metastatic renal cancer treated with sorafenib: Pilot study using dynamic contrast-enhanced Doppler ultrasound. Eur J Cancer 2006, 42:2472-2479.
31. Larsson H.B., Stubgaard M., Sondergaard L., Henriksen O. In vivo quantification of the unidirectional influx constant for Gd-DTPA diffusion across the myocardial capillaries with MR imaging. J Magn Reson Imaging 1994, 4:433-440.
32. Lassau N., Brule A., Chami L., Benatsou B., Peronneau P., Roche A. [Evaluation of early response to antiangiogenic treatment with dynamic contrast enhanced ultrasound]. J Radiol 2008, 89:549-555.
33. Lassau N., Chami L., Benatsou B., Peronneau P., Roche A. Dynamic contrast-enhanced ultrasonography (DCE-US) with quantification of tumor perfusion: A new diagnostic tool to evaluate the early effects of antiangiogenic treatment. Eur Radiol 2007, 17(Suppl 6):F89-F98.
34. Lassau N., Chebil M., Chami L., Bidault S., Girard E., Roche A. Dynamic contrast-enhanced ultrasonography (DCE-US): A new tool for the early evaluation of antiangiogenic treatment. Target Oncol 2010, 5:53-58.
35. Lassau N., Lamuraglia M., Chami L., Leclere J., Bonvalot S., Terrier P., Roche A., Le Cesne A. Gastrointestinal stromal tumors treated with imatinib: Monitoring response with contrast-enhanced sonography. AJR Am J Roentgenol 2006, 187:1267-1273.
36. Li P.C., Lee W.N. An efficient speckle tracking algorithm for ultrasonic imaging. Ultrason Imaging 2002, 24:215-228.
37. Lindberg R.A., Dewhirst M.W., Buckley B.J., Hughes C.S., Whorton A.R. Ca(2+)-dependent nitric oxide release in endothelial but not R3230Ac rat mammary adenocarcinoma cells. Am J Physiol 1996, 271:C332-C337.
38. Magnon C., Galaup A., Rouffiac V., Opolon P., Connault E., Rose M., Perricaudet M., Roche A., Germain S., Griscelli F., Lassau N. Dynamic assessment of antiangiogenic therapy by monitoring both tumoral vascularization and tissue degeneration. Gene Ther 2007, 14:108-117.
39. Marcus CD, Ladam-Marcus V, Cucu C, Bouché O, Lucas L, Hoeffel C. Imaging techniques to evaluate the response to treatment in oncology: Current standards and perspectives. Crit Rev Oncol Hematol (in press) corrected proof.
40. Meves S.H., Wilkening W., Thies T., Eyding J., Holscher T., Finger M., Schmid G., Ermert H., Postert T. Comparison between echo contrast agent-specific imaging modes and perfusion-weighted magnetic resonance imaging for the assessment of brain perfusion. Stroke 2002, 33:2433-2437.
41. Morkenborg J., Pedersen M., Jensen F.T., Stodkilde-Jorgensen H., Djurhuus J.C., Frokiaer J. Quantitative assessment of Gd-DTPA contrast agent from signal enhancement: An in vitro study. Magn Reson Imaging 2003, 21:637-643.
42. Nelson E.D., Slotoroff C.B., Gomella L.G., Halpern E.J. Targeted biopsy of the prostate: The impact of color Doppler imaging and elastography on prostate cancer detection and Gleason score. Urology 2007, 70:1136-1140.
43. Nelson E.D., Slotoroff C.B., Gomella L.G., Halpern E.J. Targeted biopsy of the prostate: The impact of color Doppler imaging and elastography on prostate cancer detection and Gleason score. Urology 2007, 70:1136-1140.
44. Niermann K.J., Fleischer A.C., Huamani J., Yankeelov T.E., Kim D.W., Wilson W.D., Hallahan D.E. Measuring tumor perfusion in control and treated murine tumors: Correlation of microbubble contrast-enhanced sonography to dynamic contrast-enhanced magnetic resonance imaging and fluorodeoxyglucose positron emission tomography. J Ultrasound Med 2007, 26:749-756.
45. O'Connor J.P., Carano R.A., Clamp A.R., Ross J., Ho C.C., Jackson A., Parker G.J., Rose C.J., Peale F.V., Friesenhahn M., Mitchell C.L., Watson Y., Roberts C., Hope L., Cheung S., Reslan H.B., Go M.A., Pacheco G.J., Wu X., Cao T.C., Ross S., Buonaccorsi G.A., Davies K., Hasan J., Thornton P., del Puerto O., Ferrara N., van Bruggen N., Jayson G.C. Quantifying antivascular effects of monoclonal antibodies to vascular endothelial growth factor: Insights from imaging. Clin Cancer Res 2009, 15:6674-6682.
46. O'Connor J.P., Jackson A., Parker G.J., Jayson G.C. DCE-MRI biomarkers in the clinical evaluation of antiangiogenic and vascular disrupting agents. Br J Cancer 2007, 96:189-195.
47. Padhani A.R., Husband J.E. Dynamic contrast-enhanced MRI studies in oncology with an emphasis on quantification, validation and human studies. Clin Radiol 2001, 56:607-620.
48. Paez-Ribes M., Allen E., Hudock J., Takeda T., Okuyama H., Vinals F., Inoue M., Bergers G., Hanahan D., Casanovas O. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 2009, 15:220-231.
49. Phillips P., Gardner E. Contrast-agent detection and quantification. Eur Radiol 2004, 14(Suppl 8):P4-P10.
50. Pollard R., Sadlowski A.R., Bloch S.H., Murray L., Wisner E.R., Griffey S., Ferrara K.W. Contrast-assisted destruction-replenishment ultrasound for the assessment of tumor microvasculature in a rat model. Technol Cancer Res Treat 2002, 1:459-470.
51. Pollard R.E., Broumas A.R., Wisner E.R., Vekich S.V., Ferrara K.W. Quantitative contrast enhanced ultrasound and CT assessment of tumor response to antiangiogenic therapy in rats. Ultrasound Med Biol 2007, 33:235-245.
52. Pollard R.E., Dayton P.A., Watson K.D., Hu X., Guracar I.M., Ferrara K.W. Motion corrected cadence CPS ultrasound for quantifying response to vasoactive drugs in a rat kidney model. Urology 2009, 74:675-681.
53. Pollard R.E., Garcia T.C., Stieger S.M., Ferrara K.W., Sadlowski A.R., Wisner E.R. Quantitative evaluation of perfusion and permeability of peripheral tumors using contrast-enhanced computed tomography. Investig Radiol 2004, 39:340-349.
54. Potdevin T.C., Fowkes J.B., Moskalik A.P., Carson P.L. Analysis of refill curve shape in ultrasound contrast agent studies. Med Phys 2004, 31:623-632.
55. Saleem A., Price P.M. Early tumor drug pharmacokinetics is influenced by tumor perfusion but not plasma drug exposure. Clin Cancer Res 2008, 14:8184-8190.
56. Tofts P.S., Brix G., Buckley D.L., Evelhoch J.L., Henderson E., Knopp M.V., Larsson H.B.W., Lee T.-Y., Mayr N.A., Parker G.J.M., Port R.E., Taylor J., Weisskoff R.M. Estimating kinetic parameters from dynamic contrast-enhanced T1-weighted MRI of a diffusable tracer: Standardized quantities and symbols. J Magn Reson Imaging 1999, 10:223-232.
57. Tweedle M.F., Wedeking P., Telser J., Sotak C.H., Chang C.A., Kumar K., Wan X., Eaton S.M. Dependence of MR signal intensity on Gd tissue concentration over a broad dose range. Magn Reson Med 1991, 22:191-194. discussion 95-96.
58. Unger E.C., McCreery T.P., Sweitzer R.H., Caldwell V.E., Wu Y.Q. Acoustically active lipospheres containing paclitaxel - A new therapeutic ultrasound contrast agent. Investigative Radiology 1998, 33:886-892.
59. von Herbay A., Schick D., Horger M., Gregor M. [Low-MI-sonography with the contrast-agent SonoVue in the diagnosis of infarction of the spleen, kidney, liver and pancreas]. Ultraschall Med 2006, 27:445-450.
60. Wei K., Jayaweera A.R., Firoozan S., Linka A., Skyba D.M., Kaul S. Quantification of myocardial blood flow with ultrasound-induced destruction of microbubbles administered as a constant venous infusion. Circulation 1998, 97:473-483.
61. Wei K., Le E., Bin J.P., Coggins M., Thorpe J., Kaul S. Quantification of renal blood flow with contrast-enhanced ultrasound. J Am College Cardiol 2001, 37:1135-1140.
62. Wei K., Ragosta M., Thorpe J., Coggins M., Moos S., Kaul S. Noninvasive quantification of coronary blood flow reserve in humans using myocardial contrast echocardiography. Circulation 2001, 103:2560-2565.
63. Wilmes L.J., Pallavicini M.G., Fleming L.M., Gibbs J., Wang D., Li K.-L., Partridge S.C., Henry R.G., Shalinsky D.R., Hu-Lowe D., Park J.W., McShane T.M., Lu Y., Brasch R.C., Hylton N.M. AG-013736, a novel inhibitor of VEGF receptor tyrosine kinases, inhibits breast cancer growth and decreases vascular permeability as detected by dynamic contrast-enhanced magnetic resonance imaging. Magn Reson Imaging 2007, 25:319-327.
64. Wink M.H., de la Rosette J.J., Laguna P., Lagerveld B.W., Wijkstra H. Ultrasonography of renal masses using contrast pulse sequence imaging: A pilot study. J Endourol 2007, 21:466-472.
65. Wink M.H., Laguna M.P., Lagerveld B.W., de la Rosette J.J., Wijkstra H. Contrast-enhanced ultrasonography in the follow-up of cryoablation of renal tumours: A feasibility study. BJU Int 2007, 99:1371-1375.
66. Yankeelov T.E., Cron G.O., Addison C.L., Wallace J.C., Wilkins R.C., Pappas B.A., Santyr G.E., Gore J.C. Comparison of a reference region model with direct measurement of an AIF in the analysis of DCE-MRI data. Magn Reson Med 2007, 57:353-361.
67. Yankeelov T.E., DeBusk L.M., Billheimer D.D., Luci J.J., Lin P.C., Price R.R., Gore J.C. Repeatability of a reference region model for analysis of murine DCE-MRI data at 7T. J Magn Reson Imaging 2006, 24:1140-1147.
68. Yankeelov T.E., Niermann K.J., Huamani J., Kim D.W., Quarles C.C., Fleischer A.C., Hallahan D.E., Price R.R., Gore J.C. Correlation between estimates of tumor perfusion from microbubble contrast-enhanced sonography and dynamic contrast-enhanced magnetic resonance imaging. J Ultrasound Med 2006, 25:487-497.
69. Zhu Y., Hall T.J. A modified block matching method for real-time freehand strain imaging. Ultrason Imaging 2002, 24:161-176.
70. Zou H.Y., Li Q., Grazzini M., Dillon R., Amundson K., Acena A., Wickman G., Shelley A., Rewolinski D., Jacobs S., Solowiej J., Murray B., McTigue M., Romines W., Lou J., Gale D., Bender S., Kania R., Shalinsky D.R., Hu-Lowe D.D. AG-028262, a novel selective VEGFR tyrosine kinase antagonist that potently inhibits KDR signaling and angiogenesis in vitro and in vivo. AACR Meeting Abstracts 2004, 2004:595c.